References
- Hammer S, Saag M, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the international AIDS Society – USA Panel. JAMA296, 827–843 (2006).
- Formulary Submission Dossier of ISENTRESS™ (Raltegravir), received October 24, 2007.
- Teppler H, Azrolan N, Chen J. Differential effect of MK-0518 and efavirenz on serum lipids and lipoproteins in antiretroviral therapy (ART)-naive patients. Presented at: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September 2006 (Abstract H-256a).
- Kassahun K, McIntosh I, Cui D et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos.35(9), 1657–1663 (2007).
- Grinsztejn B, Nguyen B-Y, Katlama C et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a Phase II randomized controlled trial. Lancet369, 1261–1269 (2007).
- Markowitz M, Nguyen B-Y, Gotuzzo F et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment-naive HIV-1 infected patients. Presented at: 16th International AIDS Conference. Toronto, Canada, 13–18 August 2006 (Abstract THLB0214).
- Butler SL, Hansen MST, Bushman FD. A quantitative assay for HIV DNA integration in vivo. Nat. Med.7(5), 631–634 (2001).
- Hazuda DJ, Felock P, Witmer M et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science287, 646–650 (2000).
- Wiskerchen M, Muesing MA. Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustainviral propagation in primary cells. J. Virol.69(1), 376–386 (1995).
- Package insert, ISENTRESS™ (raltegravir), Merk & Co., Inc. October 2007.
- Petry AS, Hanley WD, Silk G et al. Effect of Severe renal insufficiency on raltegravir (RAL) pharmacokinetics. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, USA, 17–20 September 2007 (Abstract A-1424).
- Markowitz M, Morales-Ramirez JO, Nguyen B-Y et al. Antireroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integarse, dosed as monotherapy for 10 days in treatment-naive HIV-1 infected individuals. J. Acquir. Immune Defic. Syndr.43, 509–515 (2006).
- Markowitz M, Nguyen BY, Gotuzzo E, et al.; Protocol 004 Part II Study Team. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr.46(2), 125–133 (2007).
- Cooper D, Gatell JM, Rockstroh J et al. Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Presented at: 14th Conference on Retroviruses and Opportunistic Infections (CROI). Los Angeles, CA, USA, 25–28 Febuary 2007 (Abstract 105a LB).
- Steigbigel R, Kumar P, Eron J et al. Results of BENCHMRK-2, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25–28 Febuary 2007 (Abstract 105b LB).
- Cooper D, Gatell J, Rockstroh J et al. 48-week results from BENCHMRK-1, a Phase III study of raltegravir in patients failing ART with triple-class resistant HIV-1. Presented at: 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA 3–6 February 2008 (Abstract 788).
- Steigbigel R, Kumar P, Eron J et al. 48-week results from BENCHMRK-2, a Phase III study of raltegravir in patients failing ART with triple-class resistant HIV. Presented at: 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 3–6 February 2008 (Abstract 789).
- DeJesu E, Cohen C, Elion R et al. First report of raltegravir (RAL, MK-0518) use after virologic rebound on elvitegravir (EVT, GS 9137). Presented at: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia, 22–25 July 2007 (Abstract TUPEB032).
- McColl DJ, Fransen S, Gupta S et al. Resistance and cross-resistance to first generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS-9137). Presented at: XVI International HIV Drug Resistance Workshop. Barbados, June 12–16 2007 (Abstract 9).
- Ceccherini-Silberstein F, Van Baelen K, Armenia D et al. Novel HIV-1 integrase mutations, found as minority quasispecies in patients naïve to integrase inhibitors, are associated with decreased susceptibility to integrase inhibitors in vitro. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3–6 February 2008 (Abstract 876).
- Roquebert B, Damond F, Collin G et al. Phenotypic susceptibility in vitro to raltegravir and elvitegravir and polymorphism of the integrase gene of HIV-2 clinical isolates. Presented at: 15th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, USA 3–6 February 2008 (Abstract 886).
- Murray JM, Emery S, Kelleher AD et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS.21(17), 2315–2321 (2007).
Websites
- UNAIDS: AIDS epidemic update: December 2007 http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf (Accessed on 15 May 2008)
- US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents http://aidsinfo.nih.gov/ContentFiles/AboutHIVTreatmentGuidelines_FS_en.pdf (Accessed on 20 December 2007).
- US FDA www.fda.gov/bbs/topics/NEWS/2007/NEW01726.html (Accessed on 20 December 2007)